Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price target lifted by BMO Capital Markets from $1,025.00 to $1,040.00 in a research report report published on Friday, The Fly reports. A number of other equities analysts have also weighed in on the stock. Robert W. Baird increased their target price on shares of Regeneron Pharmaceuticals […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective increased by BMO Capital Markets from $1,025.00 to $1,040.00 in a research note issued to investors on Friday morning, The Fly reports. A number of other analysts also recently issued reports on REGN. Barclays raised their target price on Regeneron Pharmaceuticals from $815.00 to $915.00 […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price target upped by Barclays from $815.00 to $915.00 in a research note issued to investors on Friday, The Fly reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on REGN. Morgan Stanley upped […]
Gateway Investment Advisers LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 6.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 910 shares of the biopharmaceutical company’s stock after selling 62 shares during the period. Gateway […]